Chronic Urticaria Therapeutics -Epidemiology Forecast to 2028

January 2019 | 50 pages | ID: C4863550E56EN
DelveInsight

Abstracts

This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'Chronic Urticaria Therapeutics - Epidemiology Forecast, 2028' report provides a comprehensive analysis of the Chronic Urticaria Therapeutics epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

MARKETS COVERED

• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2028

Chronic Urticaria Therapeutics Epidemiology

The epidemiology section covers the historical, current as well as forecasted epidemiology for Chronic Urticaria Therapeutics in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Chronic Urticaria Therapeutics outlook. It also includes the explanation of changing trends of epidemiology outlining the Chronic Urticaria Therapeutics scenario.
Chronic Urticaria Therapeutics Epidemiology Segmentation

The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Chronic Urticaria Therapeutics thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

REPORT SCOPE

• The report covers detailed overview of Chronic Urticaria Therapeutics explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Chronic Urticaria Therapeutics Report assesses the disease risk and burden and highlights the unmet needs
• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths

• 10 Year Forecast
• 7MM Coverage
• Total Cases in Chronic Urticaria Therapeutics

Key assessments

• Patient Segmentation in Chronic Urticaria Therapeutics
• Chronic Urticaria Therapeutics Risk & Burden
• Factors driving growth in a specific Chronic Urticaria Therapeutics patient population

Contents

1. REPORT INTRODUCTION

2. CHRONIC URTICARIA THERAPEUTICS EPIDEMIOLOGY OVERVIEW AT A GLANCE

2.1. Patient Share Distribution of Chronic Urticaria Therapeutics in 2016
2.2. Patient Share Distribution of Chronic Urticaria Therapeutics in 2028

3. DISEASE BACKGROUND AND OVERVIEW: CHRONIC URTICARIA THERAPEUTICS

3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment

4. EPIDEMIOLOGY AND PATIENT POPULATION

4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Chronic Urticaria Therapeutics in 7MM
4.3. Total Prevalent/ Incident Patient Population of Chronic Urticaria Therapeutics in 7MM – By Countries

5. EPIDEMIOLOGY OF CHRONIC URTICARIA THERAPEUTICS BY COUNTRIES

5.1. United States
  5.1.1. Assumptions and Rationale
  5.1.2. Prevalent/Incident Cases of the Chronic Urticaria Therapeutics
  5.1.3. Sub-Type Specific cases of the Chronic Urticaria Therapeutics
  5.1.4. Sex- Specific Cases of the Chronic Urticaria Therapeutics
  5.1.5. Diagnosed Cases of the Chronic Urticaria Therapeutics
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
  5.4.1. Assumptions and Rationale
  5.4.2. Prevalent/Incident Cases of the Chronic Urticaria Therapeutics
  5.4.3. Sub-Type Specific cases of the Chronic Urticaria Therapeutics
  5.4.4. Sex- Specific Cases of the Chronic Urticaria Therapeutics
  5.4.5. Diagnosed Cases of the Chronic Urticaria Therapeutics
5.5. France
  5.5.1. Assumptions and Rationale
  5.5.2. Prevalent/Incident Cases of the Chronic Urticaria Therapeutics
  5.5.3. Sub-Type Specific cases of the Chronic Urticaria Therapeutics
  5.5.4. Sex- Specific Cases of the Chronic Urticaria Therapeutics
  5.5.5. Diagnosed Cases of the Chronic Urticaria Therapeutics
5.6. Italy
  5.6.1. Assumptions and Rationale
  5.6.2. Prevalent/Incident Cases of the Chronic Urticaria Therapeutics
  5.6.3. Sub-Type Specific cases of the Chronic Urticaria Therapeutics
  5.6.4. Sex- Specific Cases of the Chronic Urticaria Therapeutics
  5.6.5. Diagnosed Cases of the Chronic Urticaria Therapeutics
5.7. Spain
  5.7.1. Assumptions and Rationale
  5.7.2. Prevalent/Incident Cases of the Chronic Urticaria Therapeutics
  5.7.3. Sub-Type Specific cases of the Chronic Urticaria Therapeutics
  5.7.4. Sex- Specific Cases of the Chronic Urticaria Therapeutics
  5.7.5. Diagnosed Cases of the Chronic Urticaria Therapeutics
5.8. United Kingdom
  5.8.1. Assumptions and Rationale
  5.8.2. Prevalent/Incident Cases of the Chronic Urticaria Therapeutics
  5.8.3. Sub-Type Specific cases of the Chronic Urticaria Therapeutics
  5.8.4. Sex- Specific Cases of the Chronic Urticaria Therapeutics
  5.8.5. Diagnosed Cases of the Chronic Urticaria Therapeutics
5.9. Japan
  5.9.1. Assumptions and Rationale
  5.9.2. Prevalent/Incident Cases of the Chronic Urticaria Therapeutics
  5.9.3. Sub-Type Specific cases of the Chronic Urticaria Therapeutics
  5.9.4. Sex- Specific Cases of the Chronic Urticaria Therapeutics
  5.9.5. Diagnosed Cases of the Chronic Urticaria Therapeutics

6. UNMET NEEDS OF THE CHRONIC URTICARIA THERAPEUTICS

7. APPENDIX

8. REPORT METHODOLOGY

8.1. Sources

9. DELVEINSIGHT CAPABILITIES

10. DISCLAIMER

11. ABOUT DELVEINSIGHT

Indication Specific

List Of Tables

LIST OF TABLES

Table 1: Total Prevalent/Incident Cases of the Chronic Urticaria Therapeutics in 7MM
Table 2: Total Prevalent/Incident Cases of the Chronic Urticaria Therapeutics in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Chronic Urticaria Therapeutics in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Chronic Urticaria Therapeutics in United States (2016-2028)
Table 5: Sex- Specific Cases of the Chronic Urticaria Therapeutics in United States (2016-2028)
Table 6: Diagnosed Cases of the Chronic Urticaria Therapeutics in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Chronic Urticaria Therapeutics in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Chronic Urticaria Therapeutics in Germany (2016-2028)
Table 9: Sex- Specific Cases of the Chronic Urticaria Therapeutics in Germany (2016-2028)
Table 10: Diagnosed Cases of the Chronic Urticaria Therapeutics in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Chronic Urticaria Therapeutics in France (2016-2028)
Table 12: Sub-Type Specific cases of the Chronic Urticaria Therapeutics in France (2016-2028)
Table 13: Sex- Specific Cases of the Chronic Urticaria Therapeutics in France (2016-2028)
Table 14: Diagnosed Cases of the Chronic Urticaria Therapeutics in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Chronic Urticaria Therapeutics in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Chronic Urticaria Therapeutics in Italy (2016-2028)
Table 17: Sex- Specific Cases of the Chronic Urticaria Therapeutics in Italy (2016-2028)
Table 18: Diagnosed Cases of the Chronic Urticaria Therapeutics in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Chronic Urticaria Therapeutics in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Chronic Urticaria Therapeutics in Spain (2016-2028)
Table 21: Sex- Specific Cases of the Chronic Urticaria Therapeutics in Spain (2016-2028)
Table 22: Diagnosed Cases of the Chronic Urticaria Therapeutics in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Chronic Urticaria Therapeutics in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Chronic Urticaria Therapeutics in UK (2016-2028)
Table 25: Sex- Specific Cases of the Chronic Urticaria Therapeutics in UK (2016-2028)
Table 26: Diagnosed Cases of the Chronic Urticaria Therapeutics in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Chronic Urticaria Therapeutics in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Chronic Urticaria Therapeutics in Japan (2016-2028)
Table 29: Sex- Specific Cases of the Chronic Urticaria Therapeutics in Japan (2016-2028)
Table 30: Diagnosed Cases of the Chronic Urticaria Therapeutics in Japan (2016-2028)

List Of Figures

LIST OF FIGURES

Figure 1: Total Prevalent/Incident Cases of the Chronic Urticaria Therapeutics in 7MM
Figure 2: Total Prevalent/Incident Cases of the Chronic Urticaria Therapeutics in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Chronic Urticaria Therapeutics in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Chronic Urticaria Therapeutics in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Chronic Urticaria Therapeutics in United States (2016-2028)
Figure 6: Diagnosed Cases of the Chronic Urticaria Therapeutics in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Chronic Urticaria Therapeutics in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Chronic Urticaria Therapeutics in Germany (2016-2028)
Figure 9: Sex- Specific Cases of the Chronic Urticaria Therapeutics in Germany (2016-2028)
Figure 10: Diagnosed Cases of the Chronic Urticaria Therapeutics in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Chronic Urticaria Therapeutics in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Chronic Urticaria Therapeutics in France (2016-2028)
Figure 13: Sex- Specific Cases of the Chronic Urticaria Therapeutics in France (2016-2028)
Figure 14: Diagnosed Cases of the Chronic Urticaria Therapeutics in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Chronic Urticaria Therapeutics in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Chronic Urticaria Therapeutics in Italy (2016-2028)
Figure 17: Sex- Specific Cases of the Chronic Urticaria Therapeutics in Italy (2016-2028)
Figure 18: Diagnosed Cases of the Chronic Urticaria Therapeutics in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Chronic Urticaria Therapeutics in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Chronic Urticaria Therapeutics in Spain (2016-2028)
Figure 21: Sex- Specific Cases of the Chronic Urticaria Therapeutics in Spain (2016-2028)
Figure 22: Diagnosed Cases of the Chronic Urticaria Therapeutics in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Chronic Urticaria Therapeutics in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Chronic Urticaria Therapeutics in UK (2016-2028)
Figure 25: Sex- Specific Cases of the Chronic Urticaria Therapeutics in UK (2016-2028)
Figure 26: Diagnosed Cases of the Chronic Urticaria Therapeutics in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Chronic Urticaria Therapeutics in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Chronic Urticaria Therapeutics in Japan (2016-2028)
Figure 29: Sex- Specific Cases of the Chronic Urticaria Therapeutics in Japan (2016-2028)
Figure 30: Diagnosed Cases of the Chronic Urticaria Therapeutics in Japan (2016-2028)